Targets › TOPOH1
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Sep 2027.
Open in Phaseline: the race on TOPOH1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | NALIRIFOX Combination of liposomal irinotecan (topoisomerase I inhibitor), 5-fluorouracil, leucovori | TOPOH1 | Phase 2 | Pancreatic Ductal Adenocarcinoma | Sep 2027 |
Pancreatic Ductal Adenocarcinoma (1)
small molecule (1)
Memorial Sloan Kettering Cancer Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.